SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Richard Belanger who wrote (1570)5/22/1998 11:02:00 AM
From: Bob L  Read Replies (1) of 1762
 
Rich, thanks a lot for the summary. Those of us who couldn't attend are in your debt.

Naturally, the IDEC team thinks their stuff is better, or they wouldn't be working on it. So I'll take the talk about better isotope, better antibody, etc, with several grains of salt. And calling bexxar a "salvage" treatment days after Coulter released decent first-treatment results is a bit silly. It is interesting how even top-notch people lose their scientific objectivity regarding their own work and/or investments. But being able to administer Rituxan in an ordinary chemo infusion room without nuclear medicine staff seems like a solid, objective advantage.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News